Biotechnology Research startups in San Francisco

Shennon Biotechnologies

San Francisco

ShennonBio has developed a proprietary platform that can profile millions of immune cells functionally at the single cell level at unprecedented throughput and accuracy, which resolves a key bottleneck in immunotherapy. We utilize the platform to functionally profile immune cells and their cognate antigens and apply this knowledge to develop more effective therapies against solid tumors and autoimmune diseases. Based in San Francisco next to UCSF Mission Bay, we are funded by DCVC, Foundation Capital and AV8. www.shennonbio.com

OneSkin

San Francisco

OneSkin is a longevity company on a mission to transform the way we think about skin and aging. Founded by a team of four female PhDs, OneSkin’s products focus on skin longevity. OneSkin’s proprietary peptide, OS-01, is the first ingredient designed to reduce skin's biological age by improving skin barrier, supporting DNA damage repair, and preventing the accumulation of aged cells.

Ossium Health

San Francisco

Ossium applies bioengineering to improve health, vitality, and longevity, aiming to extend human life and well-being across all life stages.

Vivodyne

San Francisco

Vivodyne is a company dedicated to accelerating the discovery of cures for human diseases. Its mission frames the company's purpose.

FibroGen

San Francisco

We are committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics to change the lives of people globally. We are also committed to being a place where our people and science thrive. Using our pioneering expertise in connective tissue growth factor (CGTF) and hypoxia-inducible factor (HIF) biology and clinical development, we hope to make a difference for people with unmet medical needs, including anemia, fibrotic disease and cancer. Pamrevlumab, an anti-CTGF human monoclonal antibody, is currently in clinical development for the treatment of locally advanced unresectable pancreatic cancer, and Duchenne muscular dystrophy. Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors and is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of chronic kidney disease. We have recently expanded our research and development portfolio to include product candidates in the immuno-oncology and autoimmune space. Want to learn more? Visit https://www.fibrogen.com/our-culture. Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved FibroGen positions are only accessible via the FibroGen Careers page at www.fibrogen.com/careers.

Rezo Therapeutics

San Francisco

Rezo is a biopharma company building a disease-agnostic, fully integrated network biology platform to dramatically increase drug development success, led by UCSF-origin founders with a proven track record of FDA-approved drugs.